Clinical Research Directory

Inclusion Criteria: * Body mass index of ≥18.0 and \<30.0 kg/m2. * In good health, as judged by the investigator based on: medical history, physical examination, vital sign assessment, clinical laboratory evaluations . * ECG without any clinically relevant abnormal findings at both screening and baseline * No history of additional risk factors for torsades de pointes (for example, heart failure, hypokalaemia, family history of long QT syndrome). * Female subjects of childbearing potential and male subjects with a female partner of childbearing potential must be willing to use highlly effective methods of contraception. Exclusion Criteria: * Any disorder which is not stable and could: * Affect the safety of the subject throughout the trial. * Influence the findings of the trial. * Impede the subject's ability to complete the trial. * Use of any medication known to prolong the QT/QTc interval within 3 months or 5 half-lives of the drug, whichever is longer, prior to randomisation. * Any medications, including St. John's wort, known to chronically alter drug absorption or elimination processes within 30 days prior to dosing. * Current use of combined hormone contraceptives or combined hormonal replacement therapy. * Subjects who have smoked (use of any type of tobacco and nicotine containing products) within the last 3 months prior to screening. * History of chronic alcohol or drug abuse within 12 months prior to screening. * Receipt of any vaccine approved for SARS-CoV-2 within 4 weeks prior to baseline and/or 2 weeks after dose. * Receipt of live, attenuated vaccines within 4 weeks prior to baseline.